Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
ATORM-S
- Development stage
- Preclinical
- Lead developer
- OrganoidSciences
- Modality
- Cell Therapies
- Administration
- Implant
01
Overview
ATORM-S is an organoid-based regenerative cell therapy developed by OrganoidSciences for the treatment of refractory salivary gland hypofunction, including radiation-induced salivary gland dysfunction and xerostomia. Composed of salivary gland organoids derived from adult tissues, ATORM-S possesses self-renewal and self-organization capabilities. Upon local transplantation into damaged salivary gland tissue, the organoids engraft and differentiate into functional salivary gland structures, thereby restoring saliva secretion and salivary gland function.
- Other names
- salivary gland organoid regenerative therapeutic
Beyond the preview
Go deeper on ATORM-S.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on ATORM-S.